An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

Trial Profile

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Gastrointestinal cancer; Glioblastoma; Large cell carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Stem CentRx
  • Most Recent Events

    • 12 Sep 2017 Results (data cut off 3 April 2017, n=31) presented at the 42nd European Society for Medical Oncology Congress
    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, 14 patients have been enrolled as of 20 Jan 2017.
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top